Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
491. |
ECCT/16/12/02 | Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial. |
Principal Investigator(s) 1. ISAAC TSIKHUTSU Site(s) in Kenya KEMRI/WRP, KERICHO |
View |
492. |
ECCT/23/06/02 | IMAGINE-TBM A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM). |
Principal Investigator(s) 1. Deborah Chepng\'eno Langat Site(s) in Kenya KEMRI/WRP CRC |
View |
493. |
ECCT/22/03/08 | CVIA 092 “ A Phase 3 Multicenter, Observer Blind, Randomized, Controlled Study to Evaluate Safety (Ages 6 Months to 45 Years) and Non-inferiority (Ages 9-12 Months) of Multi-dose and Single-dose Vial Formulations of EuTCV (Vi-CRM197 Typhoid Conjugate Vaccine) against Typbar TCV® and Lot-to-Lot Consistency of the Immune Response (Ages 9-12 Months) to Multi-dose Vial Formulation EuTCV in Healthy African Participants”. |
Principal Investigator(s) 1. Dr Lucy Koech Chepkurui Koech Site(s) in Kenya KEMRI/ KERICHO CRC |
View |
494. |
ECCT/20/04/03 | 518 & 525-SHAN6â„¢ Study Title: Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants. Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age |
Principal Investigator(s) 1. Bernhards Ogutu 2. Godfrey Allan Otieno 3. Videlis Nduba 4. Lucy Chepkurui Koech 5. samuel Gurrion Ouma 6. Janet Oyieko Site(s) in Kenya 1. Ahero Clinical Trials Unit (Kisumu county) 2. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 3. KEMRI Kondele Children’s Hospital (Kisumu county) 4. KEMRI / Walter Reed Project, Clinical Research Centre, Kericho (Kericho county) 5. KEMRI CGHR, CLINICAL RESEARCH CENTRE (Kisumu county) 6. KEMRI Centre forClinical Research(CCR)_Butere County Hospital (Kakamega county) 7. CRDR_Siaya Annex(Back-up site) (Siaya county) |
View |
495. |
ECCT/16/09/02 | Monitoring Pre-Exposure Prophylaxis for Young Adult Women ( (MPYA) Next generation real-time monitoring for PrEP adherence in young adult women. |
Principal Investigator(s) 1. Prof. Elizabeth Anne Bukusi Bukusi 2. Dr. Stella Njuguna Njuguna Site(s) in Kenya 1. KISUMU SITE (Kisumu county) |
View |